Gathering the record
Relay is organizing the evidence and source boundaries.
Unapproved GHRH-analogue / ghrelin-receptor-agonist blend
Tesa/IPA combines tesamorelin and ipamorelin, but Relay found no controlled human trial validating the blend itself. Tesamorelin has a narrow FDA-approved indication as a standalone product; ipamorelin has limited human endocrine and negative postoperative research. Those records cannot be added together as proof of synergy.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Tesa/Ipamorelin is an informal blend label for tesamorelin and ipamorelin, two distinct compounds intended to stimulate the body's growth-hormone system through different signals.
The pairing is discussed because the components act at different upstream points. Researchers would need a direct combination study to learn whether that overlap changes hormone exposure, clinical outcomes, safety, or product stability.
No controlled human trial of the blend was located. Standalone tesamorelin has a narrow approved use in adults with HIV-related abdominal-fat changes. Ipamorelin has limited acute hormone research and a negative intravenous postoperative trial.
Blend-specific benefit, interaction, compatibility, pharmacokinetics, repeated-use safety, clinical outcomes, ratio, identity, and stability all remain unknown. Separate component records cannot be added together as evidence of synergy or a combined schedule.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
Relay located primary and regulatory research for the two components separately, but no direct human study administering the fixed blend.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
The components have human data; the fixed blend does not.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Direct combination evidence, interaction data, and product standards are absent.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Tesamorelin studies did not administer ipamorelin, and ipamorelin studies did not administer tesamorelin. Component routes, findings, and regulated-product instructions cannot create a blend protocol, compatibility claim, or preparation standard. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Component-only evidence: mature standalone tesamorelin trials and label, plus limited ipamorelin endocrine data and a negative randomized postoperative trial.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Any blend-specific benefit, safety interaction, dose relationship, product compatibility, stability, sterility, pharmacokinetics, or superiority to either component.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
Its page must not convert separate component studies into combination proof.
That approval applies to the labeled standalone product for excess abdominal fat in adults with HIV and lipodystrophy, not to a blend or general weight loss.
A hormone peak is not evidence of better body composition, recovery, sleep, or longevity.
This weighs against treating endocrine activity as proof of patient benefit.
GHRHR and GHSR1a convergence is a hypothesis until directly tested.
Mechanisms
Tesamorelin is a GHRH analogue that stimulates pituitary growth-hormone release through GHRHR and has an FDA-approved standalone product for reducing excess abdominal fat in adults with HIV and lipodystrophy. Ipamorelin is a GHSR1a agonist with small acute human pharmacokinetic/pharmacodynamic studies and a randomized postoperative-ileus trial that did not demonstrate the intended clinical benefit. Complementary upstream receptor biology is mechanistically plausible, but no direct controlled evidence located establishes the fixed blend's pharmacokinetics, efficacy, safety, interaction profile, compatibility, reconstitution, or stability. The approved tesamorelin label cannot be transferred to a compounded combination.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized placebo-controlled postoperative trial
Adults undergoing bowel surgery
Ipamorelin did not demonstrate the intended postoperative clinical benefit.
Study administration: Intravenous ipamorelin or placebo
Limitations: The indication and route differ from marketed blend discussions, but the negative result is still important component evidence.
Pooled randomized placebo-controlled tesamorelin trials
Adults with HIV and excess abdominal fat
Standalone tesamorelin reduced visceral adipose tissue in its studied HIV-lipodystrophy population.
Study administration: Standalone tesamorelin or placebo
Limitations: This does not evaluate ipamorelin, the blend, general obesity, or healthy users.
Intravenous pharmacokinetic-pharmacodynamic study
Healthy male volunteers
Ipamorelin produced acute GH responses under controlled monitoring.
Study administration: Intravenous ipamorelin infusion
Limitations: Acute IV hormone response does not establish chronic clinical benefit or blend performance.
Safety snapshot
No source-qualified adverse-event pattern is represented in the current record.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryUnapproved blend — no direct controlled combination evidence located Any blend-specific benefit, safety interaction, dose relationship, product compatibility, stability, sterility, pharmacokinetics, or superiority to either component.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2025-03-01
2014-10-21 · PMID 25331030 · NCT00672074 · DOI 10.1007/s00384-014-2030-8
2010-09-01 · PMID 20554713 · DOI 10.1210/jc.2010-0490
1999-09-01 · PMID 10496658 · DOI 10.1023/A:1018955126402
No direct primary administration source was verified for this exact identity. The limitation is the finding.